CD274 and neoplasm: The higher the number of somatic variants identified per Mb the greater the probability that the tumour will respond to immune checkpoint inhibitors, however PD-L1 expression on tumour cells remains a key independent biomarker that will strongly influence the response to ICI and as such both TMB and PD-L1 biomarkers should be considered independently to access the potential benefit of ICI therapy [2].